Coya Therapeutics Q1 net loss $7.2M; cash $50.7M; FDA Fast Track for COYA 302 in ALS

Coya Therapeutics, Inc.

2026-Q1 EPS reported -$0.32 revenue$251,147

Net loss $7.2M vs $7.3M YoY; R&D expense fell to $4.1M (down $1.1M), G&A rose to $3.4M (up $1.1M).
Cash and cash equivalents $50.7M as of March 31, 2026.
FDA granted Fast Track Designation to COYA 302 for ALS on March 11, 2026.
ALSTARS Phase 2 trial now in full recruitment; topline readout expected Q1 2027.
Completed $11.1M private placement led by Dr. Reddy's ($10M) and Greenlight Capital ($1.1M).

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coya Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income Net loss was $7.2 million for the three months ended March 31, 2026. Guidance reaffirmed.

Period: quarter ended March 31, 2026
Net income: Net loss was $7.2 million for the three months ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Net loss was $7.2 million for the three months ended March 31, 2026, compared to net loss of $7.3 million for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-218198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.